Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 3
1947 7
1948 8
1949 7
1950 8
1951 17
1952 13
1953 10
1954 19
1955 27
1956 22
1957 18
1958 18
1959 13
1960 4
1961 4
1962 4
1963 8
1964 9
1965 7
1966 9
1967 9
1968 24
1969 20
1970 20
1971 9
1972 11
1973 19
1974 20
1975 22
1976 20
1977 32
1978 24
1979 15
1980 11
1981 21
1982 19
1983 27
1984 23
1985 30
1986 32
1987 38
1988 38
1989 42
1990 32
1991 41
1992 52
1993 50
1994 51
1995 49
1996 64
1997 53
1998 75
1999 58
2000 93
2001 97
2002 134
2003 98
2004 105
2005 106
2006 124
2007 160
2008 165
2009 158
2010 207
2011 228
2012 263
2013 251
2014 232
2015 240
2016 282
2017 272
2018 275
2019 272
2020 308
2021 373
2022 373
2023 311
2024 150

Text availability

Article attribute

Article type

Publication date

Search Results

5,931 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Intermittent Fasting in People With Insulin-Treated Type 2 Diabetes (INTERFAST-2)-A Randomized Controlled Trial.
Obermayer A, Tripolt NJ, Pferschy PN, Kojzar H, Aziz F, Müller A, Schauer M, Oulhaj A, Aberer F, Sourij C, Habisch H, Madl T, Pieber T, Obermayer-Pietsch B, Stadlbauer V, Sourij H. Obermayer A, et al. Among authors: muller a. Diabetes Care. 2023 Feb 1;46(2):463-468. doi: 10.2337/dc22-1622. Diabetes Care. 2023. PMID: 36508320 Free PMC article. Clinical Trial.
CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours.
Kruse B, Buzzai AC, Shridhar N, Braun AD, Gellert S, Knauth K, Pozniak J, Peters J, Dittmann P, Mengoni M, van der Sluis TC, Höhn S, Antoranz A, Krone A, Fu Y, Yu D, Essand M, Geffers R, Mougiakakos D, Kahlfuß S, Kashkar H, Gaffal E, Bosisio FM, Bechter O, Rambow F, Marine JC, Kastenmüller W, Müller AJ, Tüting T. Kruse B, et al. Among authors: muller aj. Nature. 2023 Jun;618(7967):1033-1040. doi: 10.1038/s41586-023-06199-x. Epub 2023 Jun 14. Nature. 2023. PMID: 37316667 Free PMC article.
Diagnostic genome sequencing improves diagnostic yield: a prospective single-centre study in 1000 patients with inherited eye diseases.
Weisschuh N, Mazzola P, Zuleger T, Schaeferhoff K, Kühlewein L, Kortüm F, Witt D, Liebmann A, Falb R, Pohl L, Reith M, Stühn LG, Bertrand M, Müller A, Casadei N, Kelemen O, Kelbsch C, Kernstock C, Richter P, Sadler F, Demidov G, Schütz L, Admard J, Sturm M, Grasshoff U, Tonagel F, Heinrich T, Nasser F, Wissinger B, Ossowski S, Kohl S, Riess O, Stingl K, Haack TB. Weisschuh N, et al. Among authors: muller a. J Med Genet. 2024 Jan 19;61(2):186-195. doi: 10.1136/jmg-2023-109470. J Med Genet. 2024. PMID: 37734845 Free PMC article.
Large-scale chemoproteomics expedites ligand discovery and predicts ligand behavior in cells.
Offensperger F, Tin G, Duran-Frigola M, Hahn E, Dobner S, Ende CWA, Strohbach JW, Rukavina A, Brennsteiner V, Ogilvie K, Marella N, Kladnik K, Ciuffa R, Majmudar JD, Field SD, Bensimon A, Ferrari L, Ferrada E, Ng A, Zhang Z, Degliesposti G, Boeszoermenyi A, Martens S, Stanton R, Müller AC, Hannich JT, Hepworth D, Superti-Furga G, Kubicek S, Schenone M, Winter GE. Offensperger F, et al. Among authors: muller ac. Science. 2024 Apr 26;384(6694):eadk5864. doi: 10.1126/science.adk5864. Epub 2024 Apr 26. Science. 2024. PMID: 38662832
Schlechter Schlaf verschlimmert COPD.
Müller AK, Sorichter S. Müller AK, et al. MMW Fortschr Med. 2023 Mar;165(4):30. doi: 10.1007/s15006-023-2426-x. MMW Fortschr Med. 2023. PMID: 36826655 Review. German. No abstract available.
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Huober J, Weder P, Ribi K, Thürlimann B, Thery JC, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye AM, Müller A, Membrez-Antonioli V, Gérard MA, Lemonnier J, Hawle H, Dietrich D, Boven E, Bonnefoi H; Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group. Huober J, et al. Among authors: muller a. JAMA Oncol. 2023 Oct 1;9(10):1381-1389. doi: 10.1001/jamaoncol.2023.2909. JAMA Oncol. 2023. PMID: 37561451
5,931 results